<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00743925</url>
  </required_header>
  <id_info>
    <org_study_id>AN-CVD2224</org_study_id>
    <nct_id>NCT00743925</nct_id>
  </id_info>
  <brief_title>FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes</brief_title>
  <acronym>FRANCIS-ACS</acronym>
  <official_title>FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anthera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anthera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of A 002 when added to
      high dose atorvastatin in subjects with an acute coronary syndrome (ACS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind randomized parallel group placebo controlled study in subjects
      presenting with an ACS. Subjects will be randomized to receive either A 002 500 mg once daily
      (QD) or placebo tablets in addition to 80 mg atorvastatin QD.

      Randomization must occur within ≤96 hours of hospital admission for the index ACS event, or,
      if already hospitalized, within ≤96 hours of index event diagnosis. Follow-up visits will
      occur at Weeks 2, 4, 8, 12, 16, 20, and 24 post-randomization; and monthly thereafter until
      study completion.

      All enrolled subjects will remain on treatment until all subjects have been treated for a
      minimum of 24 weeks or until the occurrence of a Major Adverse Cardiac Event (MACE). At that
      point, all active subjects (those who have not early withdrawn or those that have not already
      had a MACE) will be brought in for a Final Study Visit. Subjects who complete the Final Study
      Visit may be eligible to enroll in an open-label extension study for up to 2 years total
      study drug exposure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent changes in LDL hs-CRP, sPLA2 and other biomarkers will be compared between the 2 treatment groups.</measure>
    <time_frame>8 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of MACEs will be examined for any treatment-related trends at study completion.</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">625</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A-002 (500 mg QD) plus Atorvastatin (80 mg QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo tablets plus Atorvastatin (80 mg QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varespladib Methyl (A-002)</intervention_name>
    <description>2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>A-002</other_name>
    <other_name>Varespladib</other_name>
    <other_name>Lipitor</other_name>
    <other_name>Atorvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥18 years of age

          -  A diagnosis of unstable angina, NSTEMI, or STEMI

          -  Any one of the following criteria: Diabetes, CRP ≥2 mg/L, or metabolic syndrome

          -  Subjects must be randomized within 96 hours of the index event

          -  Percutaneous revascularization, if required or planned, must occur prior to
             randomization

        Exclusion Criteria:

        - Subjects must NOT meet any of the following exclusion criteria:

          -  Subjects enrolled in another experimental (interventional) protocol within the past 30
             days prior to Screening.

          -  Subjects treated for cancer within the previous 5 years except for skin basal cell
             carcinoma or carcinoma in situ of the cervix, with measures other than a minor,
             complete surgical excision (e.g., chemotherapy), or radiation therapy.

          -  The presence of severe liver disease with cirrhosis, recent active hepatitis, active
             chronic hepatitis, ALT or AST &gt;3 x ULN, biliary obstruction with hyperbilirubinemia
             (total bilirubin &gt;2 x ULN)

          -  Active cholecystitis, gall bladder symptoms, or potential hepato-biliary abnormalities

          -  The presence of severe renal impairment (CrCl &lt;30 mL/min or creatinine &gt;3 x ULN),
             nephrotic syndrome, or patients undergoing dialysis

          -  Uncontrolled diabetes mellitus (HbA1c &gt;11% within the last 1 month prior to Screening)

          -  Females who are nursing, pregnant, or intend to become pregnant during the time of the
             study, or females of child-bearing potential who have a positive pregnancy test during
             screening evaluation. Women of child-bearing potential must also use a reliable method
             of birth control during the study and for 1 month following completion of therapy. A
             reliable method for this study is defined as one of the following: oral or injectable
             contraceptives, IUD, contraceptive implants, tubal ligation, hysterectomy, a barrier
             method (diaphragm with spermicidal foam or jelly, or a condom).

          -  Subjects who have a history of alcohol or drug abuse within 1 year of study entry

          -  Subjects living too far from participating center or unable to return for follow-up
             visits

          -  Subjects who in the opinion of the Investigator are a poor medical or psychiatric risk
             for therapy with an investigational drug, are unreliable, or have an incomplete
             understanding of the study which may affect their ability to take drugs as prescribed
             or comply with instructions

          -  Known HIV, Hepatitis B or C virus, or tuberculosis infection

          -  Acute bacterial, fungal or viral infection

          -  Any current statin therapy at maximum recommended dosage. For atorvastatin,
             fluvastatin, lovastatin, pravastatin and simvastatin 80 mg QD at the time of the index
             event and for rosuvastatin 20 mg QD to 40 mg QD

          -  Drugs that are potent inhibitors of cytochrome P450 unless they can be withdrawn

          -  Subjects with NYHA Class III or IV heart failure, or LVEF &lt;30

          -  Subjects with moderate or severe aortic stenosis, aortic regurgitation, mitral
             stenosis or mitral regurgitation

          -  Ventricular arrhythmias requiring chronic drug treatment or ICD

          -  Subjects with no stenosis or stenosis &lt;50% on angiography

          -  Subjects with a pacemaker or persistent LBBB

          -  LDL-C &gt;200 mg/dL (5.2 mmol/L)

          -  Fasting triglyceride levels of ≥400 mg/dL (4.5 mmol/L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiological hospital of The Patriarchate of all Georgia</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tbilisi State Medical University, Al. Aladashvili University Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardio Reanimation Centre</name>
      <address>
        <city>Tbilisi</city>
        <zip>0141</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiological Clinic &quot;Guli&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tbilisi LTD Cardiology Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Cardiology Center by acad. G. Chapidze</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center of Therapy</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Clinical Hospital of Tbilisi #2</name>
      <address>
        <city>Tbilisi</city>
        <zip>0164</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Services Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Company &quot;ADAPTI&quot; The Clinic of Angiocardiology &quot;ADAPTI&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hospital Medical Union</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution</name>
      <address>
        <city>Gatchina</city>
        <zip>188300</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-State Healthcare Institution</name>
      <address>
        <city>Kemerovo</city>
        <zip>650055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk Medical Academy</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Intstitution of Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital №12</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional State Healthcare Institution</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution</name>
      <address>
        <city>Perm</city>
        <zip>614107</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Healthcare Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>190000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Healthcare Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191144</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Healthcare Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Healthcare Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution</name>
      <address>
        <city>Samara</city>
        <zip>443070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution</name>
      <address>
        <city>St-Petersburg</city>
        <zip>195197</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Healthcare Institution</name>
      <address>
        <city>St-Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution for Further Professional Training</name>
      <address>
        <city>St.Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Healthcare Institution</name>
      <address>
        <city>St.Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution Research Cardiology Institute</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyumen Cardiology Center,</name>
      <address>
        <city>Tyumen</city>
        <zip>625026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Clinical Hospital No. 27</name>
      <address>
        <city>Kharkiv</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology of Central Clinical Hospital</name>
      <address>
        <city>Kharkiv</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.T. Malaya Institute of Therapy of AMS of Ukraine</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv Medical Academy of Post-Graduate Education</name>
      <address>
        <city>Kharkiv</city>
        <zip>61178</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #1</name>
      <address>
        <city>Kyiv</city>
        <zip>02175</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Scientific Center</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Danylo Halytsky National University</name>
      <address>
        <city>Lviv</city>
        <zip>79000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional State Clinical Treatment and Diagnostics Cardiology Center</name>
      <address>
        <city>Lviv</city>
        <zip>79015</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzhgorod National University</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88014</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhya Regional Cardiological Dispensary</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhytomyr city hospital #1</name>
      <address>
        <city>Zhytomyr</city>
        <zip>10002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://www.anthera.com/</url>
    <description>Sponsor's Website</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>August 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <disposition_first_submitted>January 31, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>January 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 2, 2012</disposition_first_posted>
  <last_update_submitted>January 30, 2014</last_update_submitted>
  <last_update_submitted_qc>January 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unstable Angina</keyword>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>ACS</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>C14.280.647.124</keyword>
  <keyword>C14.280.647.500</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Varespladib methyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

